AzTrials
AzTrials

Frail ElderlyFRAIL_HEARTNCT04019405

Assessing Frailty in Elderly Patients Who Have Ischemic Heart Disease

An observational study of Frail Elderly, run by Hull University Teaching Hospitals NHS Trust at 1 site in United Kingdom.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Participants aged 80 years or over, who attend Castle Hill Hospital with either stable angina or an acute coronary syndrome will be invited to participate in the study. After induction into the study, these participants will be assessed for frailty and quality of life (QoL) using predetermined assessment tools. Read more about this study

Who is it for?
Ages 80 years and older
Conditions the study is for
Frail Elderly
How many people
150 participants
Where
1 siteUnited Kingdom
Study dates
Jul 2016to Dec 2020
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 80 years and older
  • All sexes
  • No healthy volunteers
  • Older adult

Study population: All patients (male and female) aged 80 and over and who have a primary diagnosis of ischaemic heart disease will be eligible for participation in the study.

Who may be able to join

  • Aged 80 years and above and either
  • Have been seen in the cardiology out-patient department with a diagnosis of stable angina
  • Have been admitted to Castle Hill Hospital with non-ST elevation acute myocardial infarction (NSTEMI)
  • Have been admitted to Castle Hill Hospital with ST-elevation acute myocardial infarction (STEMI)
  • Have been referred to Castle Hill Hospital for coronary angioplasty
  • Have been referred to Castle Hill Hospital for coronary artery bypass graft surgery

Who cannot join

  • Patients will be excluded from the study in the event of any of the following:
  • Patients who are unable to provide informed consent including those with advanced dementia.
  • Patients, who are not able to speak good English sufficiently to be able to understand the study information, give consent and complete study measures.
  • Patients who have a primary diagnosis of significant valvular disease

Trial locations and contacts

1 site in 1 country.

United Kingdom1 site
  • Castle Hill Hospital

    Cottingham, East Riding of Yorkshire NHS Trust, HU16 5JQ

Other trials in United Kingdom

About this study

Official title: Assessment of Frailty in Elderly People With Ischemic Heart Disease Being Considered for Revascularisation.

Participants aged 80 years or over, who attend Castle Hill Hospital with either stable angina or an acute coronary syndrome will be invited to participate in the study. After induction into the study, these participants will be assessed for frailty and quality of life (QoL) using predetermined assessment tools. Quality of life (QoL) will be assessed using the standardised SF-12 questionnaire proforma. Frailty assessment will be based on the use of the Fried Frailty Phenotype criteria and the Edmonton Frailty Scale. Patients will be reassessed at 3,9 and 24 months for their clinical outcomes, repeat frailty assessment and quality of life.

Read the detailed description

STUDY SETTINGS: Cardiology and cardiothoracic out-patients and in-patient wards of Castle Hill hospital

SAMPLE SIZE CALCULATION: FRAIL-HEART is a preliminary observational study designed to evaluate the practicality of undertaking frailty assessments in this population. The sample size of n=150 is estimated on the basis of feasibility. Investigators aim to recruit all consecutive patients who attend our department over a 1 year period. With an expected drop-out rate of 10% , investigators anticipate that it will be feasible to enrol 150 patients in the required time-frame.

PARTICIPANTS: The study target population will be patients aged 80 years or more, who are admitted or referred to the cardiology department because of underlying coronary artery disease.

IDENTIFICATION \& RECRUITMENT: These participants will be recruited into the study from outpatient cardiology clinics and from identification of suitable inpatients admitted to the cardiology and cardiothoracic units.

BASELINE ASSESSMENT: The baseline assessment will include gathering patient baseline demographic data, current diagnosis and clinical status, assessment of the comorbid conditions, and information regarding relevant investigation results including blood results, electrocardiogram (ECG), echocardiogram and coronary angiography data. Participants will be asked to complete QoL questionnaire and undergo the frailty assessments. This will entail completion of several questionnaires.

SF-12 QoL QUESTIONNAIRE: This questionnaire of 12 questions have been extensively used in research practice and validated to assess QoL in a variety of clinical settings20.

FRAILTY ASSESSMENT: This will be evaluated using both the Fried phenotype and Edmonton frailty scale. Study participants will first be asked to complete the written questionnaires. They will then have a measure of handgrip strength and if feasible will be asked to do 'get up and go' and 'five metre walk 'test as detailed in the Edmonton and Fried assessments respectively. Participants who are unable to walk will be marked as per the criteria. Where applicable, participants will be allowed to use walking aids as required.

Where applicable, the research team will also evaluate the results of coronary angiography and will undertake both SYNTAX as well as EUROSCORE calculations.

FOLLOW UP ASSESSMENTS: The study participants will be seen at 3, 9 and 24 month intervals and will be asked to complete the QoL questionnaire and undergo frailty assessment. The following variables will be recorded at each follow-up visit.

  • Patient symptoms- CCS angina class, NYHA class
  • Height, weight, BMI, Vital signs
  • Medication with dosages
  • Document all major adverse outcomes: myocardial infarction, acute cerebrovascular event, major bleeding, or unplanned re-hospitalisation.
  • Document any other adverse events such as kidney injury, transient ischaemic attack.
  • Document length of stay on ICU and total length of hospital stay (where applicable).
  • SF-12 questionnaire
  • Fried Frailty phenotype
  • Edmonton frailty scale
  • Patient perspective survey form- Two separate patients perspective have been developed depending whether the study participants are managed medically or undergo intervention and cardiac surgery.

DEATHS DURING THE STUDY PERIOD: Due to the advanced age of the study participants, it is expected that some patients might die during the study period. In such a situation the data already gathered will be retained in the study. Investigators will be advised to check on the Hull and East Yorkshire NHS Trust record systems before sending out any follow up appointments. The participant's family and relatives will not be approached after their death.

Conditions
Frail Elderly
Keywords
coronary artery disease, elderly, revascularisation, frailty
Medical subject headings
Coronary Artery Disease, Frailty

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT04019405
Study groupRoleWhat they receive
Frailty statusFrailty status will be determined by prespecified assessment tools in the study protocol. These assessment tools will be Fried Frailty phenotype model and edmonton frailty Scale.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in Quality Of Life Questionnaire

    The primary out come will be quality of life assessed by SF-12 survey forms

    Measured: baseline and 3, 9 and 24 months

Secondary outcomes (5)
  1. Change in frailty Status - Fried frailty Criteria

    To evaluate changes in frailty using the Fried frailty criteria.

    Measured: baseline and 3, 9 and 24 months

  2. Change in frailty Status - Edmonton Frailty Score

    To evaluate changes in frailty using the Edmonton frailty score.

    Measured: baseline and 3, 9 and 24 months

  3. Major adverse clinical events during hospitalization

    To evaluate major adverse clinical event (MACE) (defined as a composite of death, acute myocardial infarction, acute cerebrovascular event (CVA), and major bleeding) occurring during hospitalisation for frail versus non-frail participants of study.

    Measured: baseline and 3, 9 and 24 months

  4. Major Adverse Clinical Event

    To evaluate major adverse clinical event (MACE) (defined as a composite of death, acute myocardial infarction, acute cerebrovascular event (CVA), major bleeding, and unplanned rehospitalisation occurring at 24 months follow-up for frail versus non-frail participants of the study.

    Measured: 24 months

  5. Predictors of adverse outcome

    Patients' variables will be evaluated to determine the independent predictors of an adverse outcome (defined as death or a worsening in QOL at follow-up).

    Measured: baseline and 3, 9 and 24 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted15 Jul 2019
  2. Study startJul 2016
  3. Primary completionJun 2020
  4. Study completionDec 2020

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
150 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04019405
Sponsor's protocol ID
193997
Acronym
FRAIL_HEART
Status last verified
Apr 2022
First submitted
11 Oct 2016
Last updated
4 Apr 2022
Results posted
No
Data monitoring committee
No
Individual data sharing
No: individual participant data will not be shared

Questions about this trial

What is this clinical trial studying?

An observational study of Frail Elderly, run by Hull University Teaching Hospitals NHS Trust at 1 site in United Kingdom.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 4 Apr 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in Quality Of Life Questionnaire (time frame: baseline and 3, 9 and 24 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Apr 2022.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in